TRANSCODE THERAPEUTICS, INC. Financing Cash Flow
TRANSCODE THERAPEUTICS, INC. (RNAZ) reported Financing Cash Flow of $950.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- TRANSCODE THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $23.12M, a 226.52% increase year-over-year.
- TRANSCODE THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$455.73K, a 118.63% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $8.85M, a 45.47% increase year-over-year.
- TRANSCODE THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $31.52M, a 92.20% increase from fiscal 2024.
- TRANSCODE THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $16.40M, a 3.09% increase from fiscal 2023.
- TRANSCODE THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $15.91M, a 265542.41% increase from fiscal 2022.
- TRANSCODE THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $5.99K, a 99.98% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $950.00K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $23.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $22.67M derived: sum of 2 quarters · filed 2026-04-15 | $22.67M derived: sum of 3 quarters · filed 2026-08-14 | $31.52M 10-K · filed 2026-04-15 |
| 2025-09-30 | -$455.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$455.73K derived: sum of 2 quarters · filed 2026-08-14 | $8.40M 10-Q · filed 2025-11-14 | $15.48M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $8.85M 10-Q · filed 2026-08-14 | $15.94M derived: sum of 3 quarters · filed 2026-08-14 | $18.38M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $8.85M 10-Q · filed 2026-05-15 | $15.94M derived: sum of 2 quarters · filed 2026-05-15 | $18.38M derived: sum of 3 quarters · filed 2026-05-15 | $19.17M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $9.53M derived: sum of 2 quarters · filed 2026-04-15 | $10.31M derived: sum of 3 quarters · filed 2026-04-15 | $16.40M 10-K · filed 2026-04-15 |
| 2024-09-30 | $2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.23M derived: sum of 2 quarters · filed 2025-11-14 | $9.32M 10-Q · filed 2025-11-14 | $10.30M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $785.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $6.87M 10-Q · filed 2025-08-14 | $7.85M derived: sum of 3 quarters · filed 2025-08-14 | $15.24M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $6.09M 10-Q · filed 2025-05-14 | $7.07M derived: sum of 2 quarters · filed 2025-05-14 | $14.46M derived: sum of 3 quarters · filed 2025-05-14 | $20.82M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $978.15K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $8.37M derived: sum of 2 quarters · filed 2025-04-15 | $14.73M derived: sum of 3 quarters · filed 2025-04-15 | $15.91M 10-K · filed 2025-04-15 |
| 2023-09-30 | $7.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $13.75M derived: sum of 2 quarters · filed 2024-11-14 | $14.93M 10-Q · filed 2024-11-14 | $15.16M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $6.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $7.54M 10-Q · filed 2024-08-14 | $7.77M derived: sum of 3 quarters · filed 2024-08-14 | $7.54M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.18M 10-Q · filed 2024-05-15 | $1.41M derived: sum of 2 quarters · filed 2024-05-15 | $1.18M derived: sum of 3 quarters · filed 2024-05-15 | $1.18M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $225.82K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $0.00 derived: sum of 3 quarters · filed 2024-04-01 | $5.99K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$225.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$225.82K derived: sum of 2 quarters · filed 2023-11-14 | -$219.83K 10-Q · filed 2023-11-14 | -$210.34K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $5.99K 10-Q · filed 2023-08-14 | $15.47K derived: sum of 3 quarters · filed 2023-08-14 | $25.58M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $5.99K 10-Q · filed 2023-05-15 | $15.47K derived: sum of 2 quarters · filed 2023-05-15 | $25.58M derived: sum of 3 quarters · filed 2023-05-15 | $25.65M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $9.48K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $25.57M derived: sum of 2 quarters · filed 2023-03-31 | $25.65M derived: sum of 3 quarters · filed 2023-03-31 | $25.52M 10-K · filed 2023-03-31 |
| 2021-09-30 | $25.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $25.64M derived: sum of 2 quarters · filed 2022-11-14 | $25.51M 10-Q · filed 2022-11-14 | $25.49M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $78.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$52.76K 10-Q · filed 2022-08-15 | -$65.19K derived: sum of 3 quarters · filed 2022-08-15 | -$126.24K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$131.60K 10-Q · filed 2022-05-16 | -$144.03K derived: sum of 2 quarters · filed 2022-05-16 | -$205.08K derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$12.43K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$73.48K derived: sum of 2 quarters · filed 2022-03-31 | $1.12M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$61.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $1.13M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $1.19M 10-Q · filed 2021-08-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |